Mark de Souza
Founder at Flightpath Biosciences, Inc.
Profile
Mark P.
de Souza is the founder of Lotus Tissue Repair, Inc. (2011) where he served as President & Chief Executive Officer.
He is also the founder of Flightpath Biosciences, Inc. Dr. de Souza's former jobs include Director positions at Excelimmune, Inc., PellePharm, Inc., and Treasurer & Director at MyoTherix, Inc. He also served as Vice President-Business Development at Dyax Corp.
and as President & Director at Willow Neuroscience, Inc. (2016-2021).
Mark de Souza active positions
Companies | Position | Start |
---|---|---|
Flightpath Biosciences, Inc.
Flightpath Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Flightpath Biosciences, Inc. operates as a biotechnology company. The firm develops novel therapeutics for the treatment of tick-borne diseases and acute and post treatment Lyme disease. The company was founded by Mark de Souza, Matthew Tindall, and Curtis Scribner in 2019 and is headquartered in Berkeley, CA. | Founder | - |
Former positions of Mark de Souza
Companies | Position | End |
---|---|---|
Willow Neuroscience, Inc.
Willow Neuroscience, Inc. Medical DistributorsDistribution Services Willow Neuroscience, Inc. operates as a biotechnology company that wholesales pharmaceutical products. The company is headquartered in Emeryville, CA. | President | 2021-11-30 |
MyoTherix, Inc.
MyoTherix, Inc. Pharmaceuticals: MajorHealth Technology Myotherix, Inc. operates as a biopharmaceutical company focuses on the development of therapies. It focuses on the development of innovative therapies for patients suffering from Duchenne muscular dystrophy and other muscle disorders for which there are no treatments. The company was founded by John Kincaid and is headquartered in Emeryville, CA. | Director/Board Member | - |
PellePharm, Inc.
PellePharm, Inc. BiotechnologyHealth Technology PellePharm, Inc. engages in the operation of a biotechnology company committed to targeting rare dermatologic diseases. It develops Patidegib , an investigational topical treatment designed to mitigate the tumor burden in patients with Gorlin Syndrome and Basal Cell Carcinomas (BCCs), and other potential indications. The firm also focuses on commercializing Patidegib treatment by potentially reducing invasive and painful surgeries. The company was founded by Michael Henderson, Jean Tang, Ervin Epstein, and Philip Beachy and is headquartered in San Francisco, CA. | Director/Board Member | - |
Excelimmune, Inc.
Excelimmune, Inc. Miscellaneous Commercial ServicesCommercial Services Excelimmune, Inc. provides laboratory and biotechnology services. It is a biopharmaceutical company specializing in the development of recombinant polyclonal antibodies to create novel therapies for treating disease in humans. The firm’s next generation technology is applicable to the treatment of diseases and infections caused by common bacteria, disease-causing proteins and viral pathogens. The company was founded in 2006 by Quinton Y. Zondervan and Vincent W. Coljee and is headquartered in Lexington, MA. | Director/Board Member | - |
DYAX CORP. | Corporate Officer/Principal | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 7 |
---|---|
Dyax Corp.
Dyax Corp. Pharmaceuticals: MajorHealth Technology Dyax Corp. engages in discovery, development and commercialization of novel biotherapeutics. The company was founded by Henry E. Blair in 1989 and is headquartered in Burlington, MA. | Health Technology |
Excelimmune, Inc.
Excelimmune, Inc. Miscellaneous Commercial ServicesCommercial Services Excelimmune, Inc. provides laboratory and biotechnology services. It is a biopharmaceutical company specializing in the development of recombinant polyclonal antibodies to create novel therapies for treating disease in humans. The firm’s next generation technology is applicable to the treatment of diseases and infections caused by common bacteria, disease-causing proteins and viral pathogens. The company was founded in 2006 by Quinton Y. Zondervan and Vincent W. Coljee and is headquartered in Lexington, MA. | Commercial Services |
PellePharm, Inc.
PellePharm, Inc. BiotechnologyHealth Technology PellePharm, Inc. engages in the operation of a biotechnology company committed to targeting rare dermatologic diseases. It develops Patidegib , an investigational topical treatment designed to mitigate the tumor burden in patients with Gorlin Syndrome and Basal Cell Carcinomas (BCCs), and other potential indications. The firm also focuses on commercializing Patidegib treatment by potentially reducing invasive and painful surgeries. The company was founded by Michael Henderson, Jean Tang, Ervin Epstein, and Philip Beachy and is headquartered in San Francisco, CA. | Health Technology |
Lotus Tissue Repair, Inc.
Lotus Tissue Repair, Inc. Pharmaceuticals: MajorHealth Technology Lotus Tissue Repair, Inc. develops dermatologic treatment technologies. Its solutions include a protein replacement therapy for the treatment of dystrophic epidermolysis bullosa, a group of genetic skin disease. The company was founded by Mei Chen, Mark P. de Souza, Philip R. Reilly, David Woodley and James W. Fordyce in 2011 and is headquartered in Lexington, MA. | Health Technology |
MyoTherix, Inc.
MyoTherix, Inc. Pharmaceuticals: MajorHealth Technology Myotherix, Inc. operates as a biopharmaceutical company focuses on the development of therapies. It focuses on the development of innovative therapies for patients suffering from Duchenne muscular dystrophy and other muscle disorders for which there are no treatments. The company was founded by John Kincaid and is headquartered in Emeryville, CA. | Health Technology |
Willow Neuroscience, Inc.
Willow Neuroscience, Inc. Medical DistributorsDistribution Services Willow Neuroscience, Inc. operates as a biotechnology company that wholesales pharmaceutical products. The company is headquartered in Emeryville, CA. | Distribution Services |
Flightpath Biosciences, Inc.
Flightpath Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Flightpath Biosciences, Inc. operates as a biotechnology company. The firm develops novel therapeutics for the treatment of tick-borne diseases and acute and post treatment Lyme disease. The company was founded by Mark de Souza, Matthew Tindall, and Curtis Scribner in 2019 and is headquartered in Berkeley, CA. | Health Technology |
- Stock Market
- Insiders
- Mark de Souza